What drugs are not eligible for 340B Savings?

January 3, 2022340B, Compliance, Covered Entities, Orphan Drugs

Although the 340B drug pricing program was created by Congress to provide significant discounts on prescription drugs for eligible health care providers, a surprisingly low percentage of providers take advantage of their legal right to use it in reducing costs and filling revenue gaps. As a leading provider of 340B program-management services, we believe the primary … Read More

Understanding The 340B Program Requirements

November 8, 2021340B, 340B ESP, Bedside Prescription Delivery, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, Prescription Discounts, Requirements, Specialty Drugs, Specialty Pharmacy

What Is The 340B Drug Pricing Program? The 340B drug pricing program was created by Congress in 1992 to help fill revenue gaps experienced by healthcare providers operating on very low, or negative, margins — by providing significant discounts on prescription drugs. In a March, 2023 Fact Sheet, The American Hospital Association (AHA.org) noted, “The … Read More

Understanding the Six Categories of 340B Covered Entities

October 25, 2021340B, Compliance, Covered Entities, Requirements

The 340B Drug Pricing Program is a federal health care law that provides significant discounts and reimbursements on prescription drugs for many healthcare providers, including several categories of hospitals. This article discusses how to determine if your hospital qualifies as an eligible entity, and what you should know about each category of hospital in order … Read More

340B Outlook For 2024: Change. Change. And More Change.

October 4, 2021340B, 340B ESP, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs

What we’ve learned. What it means for your 340B program. Between late 2019 and the end of 2023, ProxsysRx’s 340B Support program went from Zero to more than $500 million in savings generated for the hospitals and health systems we serve. In spite of drug manufacturer restrictions, every one of the 13 health systems we … Read More